President Donald Trump announced his administration's plans to reduce prescription drug prices in the United States through a signed executive order that implements a "most-favored nation" policy. This initiative aims to ensure that Americans pay the lowest prices for medications available worldwide, addressing a longstanding concern regarding high drug costs.
During a press conference, Trump stated that the U.S. has been "subsidizing" the healthcare costs of other countries, which pay significantly lower prices for the same medications. He claimed that American consumers often pay up to ten times more for prescription drugs compared to other nations. He asserted that pharmaceutical companies generate a substantial portion of their profits in the U.S., despite the country's smaller share of the global population.
The executive order is expected to result in immediate reductions in drug prices, with estimates suggesting cuts of up to 90%. However, Trump did not provide specific details on how the administration would implement these reductions. He indicated that pharmaceutical companies might comply voluntarily or face federal intervention to enforce price parity with other countries.
Trump's plan also involves eliminating intermediaries known as pharmacy benefit managers (PBMs), who play a role in negotiating prices and managing drug access. Critics have pointed to PBMs as contributing to rising drug costs and increased out-of-pocket expenses for patients.
Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services, indicated that discussions would be held with pharmaceutical companies to determine fair pricing based on the best available data. The U.S. has seen drug prices rise significantly in recent years, with consumers bearing an increasing share of healthcare costs.